Medical management of gastro-esophageal reflux in healthy infants. Issue 8 (27th December 2022)

• Record Type: Journal Article
• Authors: Chevalier, Isabelle; Beck, Carolyn E; Doré-Bergeron, Marie-Joëlle; Orkin, Julia
• Is Part Of: Paediatrics & Child Health. Volume 27:Issue 8(2022)
• Page Start: 503
• Page End: 506
• Publication Date: 2022-12-27
• Subjects: Children -- Gastroesophageal reflux -- Gastroesophageal reflux disease -- H2 receptor antagonists -- Infants -- Prokinetics -- Proton pump inhibitor; Pediatrics -- Periodicals; Children -- Health and hygiene -- Periodicals; 618.92
• DOI: 10.1093/pch/pxac068
• Languages: English
• ISSNs: 1205-7088

Abstract

Abstract: Clinical symptoms attributed to gastro-esophageal reflux disease (GERD) in healthy term infants are non-specific and overlap with age-appropriate behaviours. This practice point reviews the evidence for medically recommended management of this common condition. Current recommendations to manage GERD include feeding modifications such as thickening feeds or avoiding cow's milk protein. There is limited evidence for pharmacological management, including acid suppressive therapy or prokinetic agents, with the risks of such treatments often outweighing possible benefits due to significant safety and side effect concerns. Acid-suppressive therapy should not be routinely used for infants with GERD and is most likely to be useful in the context of symptoms that suggest erosive esophagitis. Evidence for managing symptoms attributed to GERD in otherwise healthy term infants less than 1 year of age is presented, and the over-prescription of medications in this population is discouraged. Anticipatory guidance regarding the natural resolution of reflux symptoms is recommended.